We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PTC:NASDAQPTC Inc. Analysis

Data as of 2026-09-07 - not real-time

$141.02

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

At $141.02, PTC Inc. shows no decisive moving-average alignment, leaving the trend neutral. Over a rolling month the price has gained 19.0%. Relative strength is 43.0 — neutral — and the MACD signal is bearish. Recent trading has carved out support near $140.00 and resistance around $159.46.
On valuation the read is undervalued — earnings multiple of 13.7 versus a 33.2 sector average, below the peer group. Analyst price targets sit 22.9% above the current price. Revenue is contracting at 6.8% on a 41.4% profit margin.
The composite risk read is 6/10, putting it in elevated territory. With 30-day volatility of 43.6%, a beta of 0.48 and a maximum drawdown of 47.5%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 5/10 long-term conviction.

Top Market Events

PTC Inc. PTC now presents a more balanced investment debate after a sharp pullback reset expectations and valuation....PTC's valuation reset and buybacks improve its risk-reward profile, but weak revenue, margin pressure and a demanding...WS Amati Global Innovation Fund, managed by a UK-based equity management firm from AMAti Global Investors, released its...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 148.72
  • MACD momentum is negative
  • 30-day price change of +19.0%

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • P/E of 13.7 versus sector average of 33.2
  • Trading below the 200-day average of 148.72
  • Analyst targets imply +22.9% versus the current price

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 13.7 versus sector average of 33.2
  • Analyst targets imply +22.9% versus the current price
  • Profit margin of 41.4% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth-6.80%
Profit Margin41.43%
P/E Ratio13.7
ROE35.05%
ROA11.54%
Debt/Equity46.34
P/B Ratio4.5
Op. Cash Flow$955.3M
Free Cash Flow$1.0B
Industry P/E33.2

Technical Analysis

TrendNeutral
RSI43.0
Support$140.00
Resistance$159.46
MA 20$151.41
MA 50$136.51
MA 200$148.72
MACDBearish
VolumeIncreasing
Fear & Greed Index94.11

Valuation

Fair Value$108.76
Target Price$173.35
Upside/Downside22.93%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.48
Volatility43.63%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.